Incidences and Trends of Second Cancers in Female Breast Cancer Patients: A Fixed Inception Cohort-based Analysis (United States)
Tóm tắt
To determine incidences and time trends of second cancers among female breast cancer patients. Using data of the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program, we designed three inception cohorts: 1975–1977 (n=25,920), 1983–1985 (n=32,722) and 1991–1993 (n=40,819), and analyzed their incidences of second cancers during the first 8 years after initial breast cancer diagnosis. Between the 1970s and the 1990s, the incidence rate of malignant second cancer significantly increased among female breast cancer patients, of which second non-Hodgkin’s lymphoma and kidney cancer increased by about 150%, while second cancers of the thyroid, uterine corpus and skin melanoma increased 80%, and cancer of the lung increased 50%. The patterns of trend of second cancers were somewhat similar to those of the general population except for second endometrial cancer at all ages and second leukemia and skin melanoma among young patients aged 20–49. In the 1990s, the risk ratios (RR) of all sites cancer were found to be 5.5 (95% CI=5.0–6.1) for age 20–49, 1.3 (1.3–1.4) for age 50–64, and 1.2 (1.1–1.2) for age 65 and over, comparing breast cancer patients to general population. Additionally, radiotherapy slightly increased the risks of second leukemia (RR=1.8, 1.2–2.8), and second endometrial (RR=1.3, 1.0–1.6) and breast (RR=1.2, 1.1–1.3) cancers. The fixed inception cohort method is valid for analyzing cancer registry-based second cancer data. By this method, we found that the incidence of second cancer has substantially increased among female breast cancer patients over the past 25 years. Observed changes in incidence may partially reflect the effect of treatments. Because the absolute number of affected patients is small, however, the breast cancer treatments have remained safe for most patients.
Tài liệu tham khảo
Sadetzki S, Calderon-Margalit R, Peretz C, Novikov I, Barchana M, Papa MZ (2003) Second primary breast and thyroid cancers (Israel). Cancer Causes Control 14:367–375
Zheng T, Holford TR, Chen Y, Ma JZ, Flannery J, Liu W, Russi M, Boyle P (1996) Time trend and age-period-cohort effect on incidence of thyroid cancer in Connecticut, 1935–1992. Int J Cancer 67:504–509
Colonna M, Grosclaude P, Remontet L, Schvartz C, Mace-Lesech J, Velten M, Guizard A, Tretarre B, Buemi AV, Arveux P, Esteve J (2002) Incidence of thyroid cancer in adults recorded by French cancer registries (1978–1997). Eur J Cancer 38:1762–1768
Liu S, Semenciw R, Ugnat AM, Mao Y (2001) Increasing thyroid cancer incidence in Canada, 1970–1996: time trends and age-period-cohort effects. Br J Cancer 85:1335–1339
Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 9 Regs Public-Use, Nov 2003 Sub (1973–2001), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2004: based on the November 2003 submission
Breslow NE, Day NE (1987) Statistical methods in cancer research, Vol. 2. The design and analysis of cohort studies. International Agency for Research on Cancer, Lyon
Schoenberg BS, Myers MH (1977) Statistical methods for studying multiple primary malignant neoplasms. Cancer 40:1892–1898
Nicodemus KK, Sweeney C, Folsom AR (2004) Evaluation of dietary, medical and lifestyle risk factors for incident kidney cancer in postmenopausal women. Int J Cancer 108:115–121
Hu J, Mao Y, White K (2003) Overweight and obesity in adults and risk of renal cell carcinoma in Canada. Soz Praventivmed 48:178–185
Tate R, Iddenden R, Harnden P, Morris E, Craigs C, Bennett C, Brook C, Haward RA, Forman D (2003) Increased incidence of renal parenchymal carcinoma in the Northern and Yorkshire region of England, 1978–1997. Eur J Cancer 39:961–967
Gross TP, Wise RP, Knapp DE (1989) Antihypertensive drug use. Trends in the United States from 1973 to 1985. Hypertension 13:I113–I118
Beral V, Peterman T, Berkelman R, Jaffe H (1991) AIDS-associated non-Hodgkin lymphoma. Lancet 337:805–809
Gail MH, Pluda JM, Rabkin CS, Biggar RJ, Goedert JJ, Horm JW, Sondik EJ, Yarchoan R, Broder S (1991) Projections of the incidence of non-Hodgkin’s lymphoma related to acquired immunodeficiency syndrome. J Natl Cancer Inst 83:695–701
Kinlen LJ (2000) Non-Hodgkin’s lymphoma after immunosuppressive therapy. Gut 47:462–463
Elwood JM, Jopson J (1997) Melanoma and sun exposure: an overview of published studies. Int J Cancer 73:198–203
Travis WD, Lubin J, Ries L, Devesa S (1996) United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. Cancer 77:2464–2470
McPherson CP, Sellers TA, Potter JD, Bostick RM, Folsom AR (1996) Reproductive factors and risk of endometrial cancer. The Iowa Women’s Health Study. Am J Epidemiol 143:1195–1202
Archer DF (2004) Neoplasia of the female reproductive tract: effects of hormone therapy. Endocrine 24:259–263
Dunn BK, Wickerham DL, Ford LG (2005) Prevention of hormone-related cancers: breast cancer. J Clin Oncol 23:357–367
Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F (2005) Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114:448–454
Stewart HJ (1992) The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group. J Natl Cancer Inst Monogr 117–120
Peters-Engl C, Frank W, Danmayr E, Friedl HP, Leodolter S, Medl M (1999) Association between endometrial cancer and tamoxifen treatment of breast cancer. Breast Cancer Res Treat 54:255–260
Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfversward C, Skoog L, Somell A, Theve T, Wilking N, et al (1989) Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1:117–120
Ursic Vrscaj M, Kovacic J, Bebar S, Djurisic A, Fras PA, Robic V (2001) Endometrial and other primary cancers after tamoxifen treatment of breast cancer—results of retrospective cohort study. Eur J Obstet Gynecol Reprod Biol 95:105–110
Sasco AJ, Chaplain G, Amoros E, Saez S (1996) Endometrial cancer following breast cancer: effect of tamoxifen and castration by radiotherapy. Epidemiology 7:9–13
Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N (1995) Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies Stockholm Breast Cancer Study Group. J Natl Cancer Inst 87:645–651
Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527–537
Matesich SM, Shapiro CL (2003) Second cancers after breast cancer treatment. Semin Oncol 30:740–748
Kyle RA (1982) Second malignancies associated with chemotherapeutic agents. Semin Oncol 9:131–142
Fisher B, Rockette H, Fisher ER, Wickerham DL, Redmond C, Brown A (1985) Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: the NSABP experience. J Clin Oncol 3:1640–1658
Curtis RE, Boice JD, Jr., Stovall M, Bernstein L, Greenberg RS, Flannery JT, Schwartz AG, Weyer P, Moloney WC, Hoover RN (1992) Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 326:1745–1751
Hahn P, Nelson N, Baral E (1994) Leukemia in patients with breast cancer following adjuvant chemotherapy and/or postoperative radiation therapy. Acta Oncol 33:599–602
Chaplain G, Milan C, Sgro C, Carli PM, Bonithon-Kopp C (2000) Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study. J Clin Oncol 18:2836–2842
Carli PM, Sgro C, Parchin-Geneste N, Isambert N, Mugneret F, Girodon F, Maynadie M (2000) Increase therapy-related leukemia secondary to breast cancer. Leukemia 14:1014–1017
Crump M, Tu D, Shepherd L, Levine M, Bramwell V, Pritchard K (2003) Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:3066–3071
Goggins W, Gao W, Tsao H (2004) Association between female breast cancer and cutaneous melanoma. Int J Cancer 111:792–794
Hemminki K, Vaittinen P (1997) Interaction of breast cancer and melanoma genotypes. Lancet 350:931–932
Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Masback A, Westerdahl J, Olsson H, Ingvar C (2000) High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 92:1260–1266
Chen Y, Thompson W, Semenciw R, Mao Y (1999) Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev 8:855–861
Bernstein JL, Thompson WD, Risch N, Holford TR (1992) Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer. Am J Epidemiol 136:925–936
Gao X, Fisher SG, Emami B (2003) Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys 56:1038–1045
de Koning HJ, van Dongen JA, van der Maas PJ (1994) Changes in use of breast-conserving therapy in years 1978–2000. Br J Cancer 70:1165–1170
Harris JR, Recht A, Connolly J, Cady B, Come S, Henderson IC, Koufman C, Love S, Schnitt S, Osteen R (1990) Conservative surgery and radiotherapy for early breast cancer. Cancer 66:1427–1438
Neugut AI, Weinberg MD, Ahsan H, Rescigno J (1999) Carcinogenic effects of radiotherapy for breast cancer. Oncology (Huntingt) 13:1245–1256. discussion 1257: 1261–1245
Roychoudhuri R, Evans H, Robinson D, Moller H (2004) Radiation-induced malignancies following radiotherapy for breast cancer. Br J Cancer 91:868–872
Harvey EB, Brinton LA (1985) Second cancer following cancer of the breast in Connecticut, 1935–82. Natl Cancer Inst Monogr 68:99–112